FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.